actos gain plus weight
Click on image below to visit actos Online Page
Business Editors/Health & Medical Writers
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–April 7, 2000
ACTOS(R) (pioglitazone hydrochloride), which is distributed by Takeda Pharmaceuticals America, Inc. and co-promoted with Eli Lilly and Company, has been the leading thiazolidinedione (TZD) for new prescriptions written by endocrinologists since February 25, 2000, according to IMS Health data.
TZDs are a preferred therapy option for reducing insulin resistance, an underlying cause of type 2 diabetes.
“It is important to see that the experts in diabetes care, endocrinologists, are choosing ACTOS for their patients who require an insulin sensitizing therapy,” said William Wishner, M.D., Associate Director, External Medical Affairs.
In addition to being the leader among endocrinologists, IMS Health data also show that ACTOS has been the fastest growing product in the TZD market by all measurements, including total prescriptions, total prescription market share, new prescriptions and new prescription market share, since September 1999.
While 0.4% of U.S. physicians are endocrinologists, they account for approximately 12% of total TZD prescriptions written in the U.S.
“We believe that physicians are beginning to really understand the benefits of ACTOS, which should also be helpful to patients transitioning from Rezulin(R) (troglitazone),” said Wishner.
Advertisement
Aciphex phentermine actos actos ranitidine
Save, discount actos 30mg
Actos 30mg
Diabetes drug lawsuit heart attack from actos
Cheap actos
Pravachol actos alphagan
cheap actos